drugset
drugset / Trial / NCT05885451

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants

NCT05885451 ↗

Phase 1 Completed 18 enrolled Amgen
RandomizedParallel-groupDouble-blindBasic science

Summary

The primary objective of this study is to characterize the pharmacokinetics (PK) profile of a single dose of AMG 592 administered subcutaneously in healthy Japanese participants.

Timeline

Start
2019-01-29
Primary completion
2019-04-11
Completion
2019-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Efavaleukin alfa Protein / enzyme biologic — Subcutaneous

Indications

chronic graft versus host disease